A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CNTO 5825 Following a Single Intravenous or a Single Subcutaneous Administration in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2010
At a glance
- Drugs CNTO 5825; CNTO 5825
- Indications Hypersensitivity
- Focus Adverse reactions
- 30 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2010 Actual patient number (56) added as reported by ClinicalTrials.gov.
- 21 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.